ADAPTIVE BIOTECHNOLOGIES CORPORATION Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest
ADAPTIVE BIOTECHNOLOGIES CORPORATION (ADPT) had Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest of $150.66 million as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Balance Sheet › Equity › Equity, Including Portion Attributable to Noncontrolling Interest
us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest · last filed 2026-08-04
- 2026-06-30: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $150.66M.
- 2026-03-31: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $224.24M.
- 2025-12-31: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $225.00M.
- 2025-09-30: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $204.25M.
| Period end | Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest |
|---|---|
| 2026-06-30 | $150.66M 10-Q · filed 2026-08-04 |
| 2026-03-31 | $224.24M 10-Q · filed 2026-08-04 |
| 2025-12-31 | $225.00M 10-Q · filed 2026-08-04 |
| 2025-09-30 | $204.25M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $179.54M 10-Q · filed 2026-08-04 |
| 2025-03-31 | $190.22M 10-Q · filed 2026-08-04 |
| 2024-12-31 | $202.49M 10-Q · filed 2026-08-04 |
| 2024-09-30 | $223.57M 10-Q · filed 2025-11-05 |
| 2024-06-30 | $241.43M 10-Q · filed 2025-11-05 |
| 2024-03-31 | $274.77M 10-Q · filed 2025-08-05 |
| 2023-12-31 | $308.28M 10-K · filed 2026-02-26 |
| 2023-09-30 | $361.64M 10-Q · filed 2024-11-07 |
| 2023-06-30 | $395.97M 10-Q · filed 2024-11-07 |
| 2023-03-31 | $423.95M 10-Q · filed 2024-08-01 |
| 2022-12-31 | $464.10M 10-K · filed 2026-02-26 |
| 2022-09-30 | $487.81M 10-Q · filed 2023-11-09 |
| 2022-06-30 | $518.32M 10-Q · filed 2023-11-09 |
| 2022-03-31 | $553.25M 10-Q · filed 2023-08-02 |
| 2021-12-31 | $604.10M 10-K · filed 2025-03-03 |
| 2021-09-30 | $651.54M 10-Q · filed 2022-11-03 |
| 2021-06-30 | $693.31M 10-Q · filed 2022-11-03 |
| 2021-03-31 | $725.72M 10-Q · filed 2022-08-03 |
| 2020-12-31 | $743.27M 10-K · filed 2024-02-29 |
| 2020-09-30 | $775.05M 10-Q · filed 2021-11-03 |
| 2020-06-30 | $529.94M 10-Q · filed 2021-11-03 |
| 2020-03-31 | $551.56M 10-Q · filed 2021-08-04 |
| 2019-12-31 | $571.04M 10-K · filed 2023-02-14 |
| 2018-12-31 | -$258.11M 10-K · filed 2022-02-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |